Benjamin Halladay - 14 Mar 2024 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Financial Officer
Signature
/s/ Sheldon L. Koenig, by power of attorney
Issuer symbol
ESPR
Transactions as of
14 Mar 2024
Net transactions value
$0
Form type
4
Filing time
15 Mar 2024, 16:32:14 UTC
Previous filing
15 Mar 2023
Next filing
18 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +170,000 +230% $0.000000 243,936 14 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ESPR Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 14 Mar 2024 Common Stock 200,000 $2.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2024.